Hans C. Lee, MD

•  Multiple Myeloma
• Waldenström's Macroglobulinemia
• AL amyloidosis

Dr. Lee is board-certified in hematology and medical oncology and serves as the Director of Multiple Myeloma Research at the Sarah Cannon Research Institute. Prior to joining SCRI Oncology Partners, he spent over 10 years as a faculty member at the University of Texas MD Anderson Cancer Center where he served as the Director of Multiple Myeloma Clinical Research. Dr. Lee’s clinical and research efforts are focused on advancing the care and treatment of patients with plasma cell dyscrasias including multiple myeloma, AL amyloidosis, and Waldenström Macroglobulinemia. His research has been funded by the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR) and highlighted in 125+ peer-reviewed publications.